found that UCB-MSCs, because of the existence of GDF-15, enhanced Aβ plaque clearance by upregulation of both insulin-degrading enzyme (IDE) and neprilysin expression in microglial cells in vivo, clarifying another therapeutic appliance for AD [151]. Here, GDF15 is linked to Alzheimer disease.